{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:22:17Z","timestamp":1740162137225,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen-Cilag Ltd, Napp and Blood Cancer UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-022-00758-7","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:05:48Z","timestamp":1669709148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulnaz","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5157-7043","authenticated-orcid":false,"given":"Victoria","family":"Stalker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherin","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindriska","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Schey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-7564","authenticated-orcid":false,"given":"Mark","family":"Drayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"758_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","volume":"53","author":"LM Knudsen","year":"1994","unstructured":"Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207\u201312.","journal-title":"Eur J Haematol"},{"key":"758_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Fern\u00e1ndez-Llama P, Bosch F, Montol\u00edu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889\u201393.","journal-title":"Arch Intern Med"},{"key":"758_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","volume":"91","author":"R Torra","year":"1995","unstructured":"Torra R, Blad\u00e9 J, Cases A, L\u00f3pez-Pedret J, Montserrat E, Rozman C, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91:854\u20139.","journal-title":"Br J Haematol"},{"key":"758_CR4","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219\u201326.","journal-title":"J Clin Oncol"},{"key":"758_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.24335","volume":"91","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499\u2013502.","journal-title":"Am J Hematol"},{"key":"758_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337\u201341.","journal-title":"Leuk Lymphoma"},{"key":"758_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0268-960X(99)90014-0","volume":"13","author":"AD Clark","year":"1999","unstructured":"Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13:79\u201390.","journal-title":"Blood Rev"},{"key":"758_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14394","volume":"180","author":"F Evison","year":"2018","unstructured":"Evison F, Sangha J, Yadav P, Aung YS, Sharif A, Pinney JA, et al. A population-based study of the impact of dialysis on mortality in multiple myeloma. Br J Haematol. 2018;180:588\u201391.","journal-title":"Br J Haematol"},{"key":"758_CR9","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S1557-9190(11)70555-8","volume":"9","author":"MT Drayson","year":"2009","unstructured":"Drayson MT, Behrens J, Cohen DR, Iggo N, Gregory WM, Bell S, et al. A351 serum FLC levels can be reduced rapidly; lower levels are associated with renal recovery. Clin Lymphoma Myeloma. 2009;9:S57\u2013S58.","journal-title":"Clin Lymphoma Myeloma"},{"key":"758_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357.","journal-title":"J Clin Oncol"},{"key":"758_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/sonc.2002.34872","volume":"29","author":"V Gandhi","year":"2002","unstructured":"Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002;29:4\u201311.","journal-title":"Semin Oncol"},{"key":"758_CR12","doi-asserted-by":"crossref","unstructured":"P\u00f6nisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, et al. Successful treatment with Bortezomib in combination with Bendamustine and prednisone of patients with newly diagnosed\/untreated multiple myeloma and light chain induced renal failure. Blood. 2011;118:2938.","DOI":"10.1182\/blood.V118.21.2938.2938"},{"key":"758_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357.","journal-title":"J Clin Oncol"},{"key":"758_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2017.17924","volume":"318","author":"F Bridoux","year":"2017","unstructured":"Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. JAMA. 2017;318:2099\u2013110.","journal-title":"JAMA."},{"key":"758_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-9-55","volume":"9","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. 2008;9:55.","journal-title":"Trials."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00758-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00758-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:06:18Z","timestamp":1669709178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00758-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00758-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors completed the ICMJE disclosure form. The following personal or financial relationships relevant to this manuscript existed during the conduct of the study. KR reports honoraria, research grant from Janssen, Celgene, Takeda, and Amgen. He also reports advisory boards from Celgene, Takeda, Janssen, Amgen, Abbvie, Sanofi, Oncopeptides, Karyopharm, GSK, Adaptive biotech, Pfizer, and speaker\u2019s bureau from Celgene, Takeda and Adaptive Biotech. MD owns shares in Abingdon Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}